A Phase II Study of Combined Fulvestrant (Faslodex) and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Everolimus (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Dec 2015 Results assessing genomic evolution on endocrine therapy and mTOR inhibition presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 02 Jun 2015 Results assessing genomic alterations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.